Complete response with fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor in BRAF-mutated metastatic colorectal cancer: a case report.

Abstract:

Background:Patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis. The Southwest Oncology Group (SWOG) 1406 study evaluated the efficacy of vemurafenib in combination with irinotecan and cetuximab for simultaneous inhibition of epidermal growth factor receptor (EGFR) and BRAF in patients with BRAFV600E-mutated mCRC. Although the combination achieved higher progression-free survival (PFS) and disease control rates (DCRs), there was no complete response (CR) for the drug combination. In this case report, we report the complete recession of metastasis in a patient treated with irinotecan, cetuximab, vemurafenib, and 5-fluorouracil. Case presentation:A 44-year-old male patient with hepatitis B was diagnosed with right-sided colon adenocarcinoma. He was treated with capecitabine plus oxaliplatin as postoperative adjuvant chemotherapy for eight cycles with a disease-free survival (DFS) of 1 year before the emergence of peritoneal and pelvic metastases. BRAFV600E mutation was positive and chemotherapy included 12 courses of 5-fluorouracil, vemurafenib, irinotecan, and cetuximab. Complete response with recession of metastases was observed. Conclusion:The combination of fluorouracil and irinotecan with a BRAFV600E and EGFR inhibitor may have synergistic action, leading to recession of secondary metastases in patients with BRAFV600E-mutated colorectal cancer.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Wang Z,Dai WP,Zang YS

doi

10.2147/OTT.S180845

subject

Has Abstract

pub_date

2019-01-08 00:00:00

pages

443-447

issn

1178-6930

pii

ott-12-443

journal_volume

12

pub_type

  • Combined detection of IL-6 and IL-8 is beneficial to the diagnosis of early stage esophageal squamous cell cancer: a preliminary study based on the screening of serum markers using protein chips.

    abstract:Background:The diagnosis rate of early stage esophageal squamous cell carcinoma (ESCC) is low due to the lack of specific tumor markers. Seeking for these markers is beneficial to improve the early diagnosis rate and the prognosis of patients. This study profiles the differentially expressed proteins of early stage ESC...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S171242

    authors: Tong Q,Wang XL,Li SB,Yang GL,Jin S,Gao ZY,Liu XB

    更新日期:2018-09-12 00:00:00

  • Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer.

    abstract::Angiogenesis plays an essential role in the development of most solid tumors by delivering nutrients and oxygen to the tumor. Therefore, anti-angiogenic therapy, particularly anti-VEGF and anti-VEGF receptor (VEGFR) therapy, has been a popular strategy to treat cancer. However, anti-angiogenic therapy does not signifi...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S276150

    authors: Tian W,Cao C,Shu L,Wu F

    更新日期:2020-11-24 00:00:00

  • Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation.

    abstract:BACKGROUND:Hepatocellular carcinoma (HCC) patients with fever as the initial presentation are extremely rare. Our aim was to investigate the clinical characteristics and prognosis of patients with this disease. PATIENTS AND METHODS:The clinical features were analyzed in a retrospective study of 63 HCC patients with fe...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S109023

    authors: Gong ZJ,Guo W,Sun YF,Zhang X,Qiu SJ,Zhou J,Fan J,Yang XR

    更新日期:2016-10-13 00:00:00

  • Temozolomide Combined With Capecitabine In The Treatment Of Mixed Neuroendocrine Carcinoma Of The Lung With Poor Tolerance After Repeated Radiochemotherapy: A Case Report And Literature Review.

    abstract::The incidence of lung neuroendocrine carcinomas, which originate from lung neuroendocrine cells, is 1.35/100,000, among which mixed neuroendocrine carcinomas are very rare. Because of the heterogeneity and significant differences in sensitivity to treatments, there is no effective treatment, and the prognosis is poor....

    journal_title:OncoTargets and therapy

    pub_type:

    doi:10.2147/OTT.S210699

    authors: Zhang B,Wang D,Zhang X,Cui X,Kong L,Li M,Yu J

    更新日期:2019-11-14 00:00:00

  • Serum dickkopf-1 as a biomarker in screening gastrointestinal cancers: a systematic review and meta-analysis.

    abstract:OBJECTIVE:Despite advances in the early diagnosis of gastrointestinal (GI) cancers, these cancers are often being detected rather late in their course. Emerging published data on the accuracy of dickkopf-1 (DKK1) for diagnosing GI cancers are inconsistent. The purpose of this systematic review and meta-analysis was to ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S93152

    authors: Liang B,Zhong L,He Q,Wang S,Pan Z,Wang T,Zhao Y

    更新日期:2015-10-22 00:00:00

  • B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data.

    abstract:Purpose:B7 homologue 6 (B7-H6) has been found at an up-regulated level in multiple cancer cells and identified to be positively correlated with inferior clinical features. In non-Hodgkin lymphoma (NHL), however, the roles of B7-H6 and the underlying mechanism of action remain unclear. Through in vivo and in vitro exper...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S257512

    authors: Yang S,Yuan L,Wang Y,Zhu M,Wang J,Ke X

    更新日期:2020-06-18 00:00:00

  • Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study.

    abstract:Purpose:Non-small cell lung cancer (NSCLC) patients with EGFR mutation are suffering from a high incidence of brain metastasis (BM). It is still controversial whether cranial radiotherapy could be delayed when the EGFR-tyrosine kinase inhibitors (TKIs) used as first-line therapy for EGFR-positive patients with BM. This...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S223216

    authors: An N,Wang H,Li J,Zhai X,Jing W,Jia W,Kong L,Zhu H,Yu J

    更新日期:2019-10-08 00:00:00

  • Correlation between high-resolution computed tomography lung nodule characteristics and EGFR mutation in lung adenocarcinomas.

    abstract:Background:The aim of this study was to investigate the correlation of EGFR mutation on the high-resolution computed tomography (HRCT) features in lung adenocarcinoma. Patients and methods:A total of 121 patients were diagnosed with lung adenocarcinoma from January 2014 to December 2016. The correlation of indexes (ge...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S184217

    authors: Nie Y,Liu H,Tan X,Wang H,Li F,Li C,Han P,Lyv X,Xu X,Guo M

    更新日期:2019-01-10 00:00:00

  • A novel curcumin derivative CL-6 exerts antitumor effect in human gastric cancer cells by inducing apoptosis through Hippo-YAP signaling pathway.

    abstract:Purpose:Gastric carcinoma is the second most frequently diagnosed cancer and leading cause of cancer death in China. As a new generation of cancer therapeutic drug, CL-6, a curcumin derivative, shows better bioavailability than curcumin, which has shown anticancer effects in gastric cancer (GC). However, whether CL-6 s...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S196914

    authors: Ye C,Wang W,Xia G,Yu C,Yi Y,Hua C,Tu F,Shen L,Chen C,Sun W,Zheng Z

    更新日期:2019-03-27 00:00:00

  • LncRNA CASC15 Functions As An Unfavorable Predictor Of Ovarian Cancer Prognosis And Inhibits Tumor Progression Through Regulation Of miR-221/ARID1A Axis.

    abstract:Background:LncRNA cancer susceptibility candidate 15 (CASC15) has been demonstrated to act as an oncogene in different cancers; however, its role in ovarian cancer remains elusive. Methods:Quantitative real-time PCR (qRT-PCR) was performed to examine the expression of lncRNA CASC15. Kaplan-Meier survival analysis was ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S219900

    authors: Shi Y,Gao S,Zheng Y,Yao M,Ruan F

    更新日期:2019-10-23 00:00:00

  • Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer.

    abstract:PURPOSE:The aim of this study was to evaluate the therapeutic efficacy and safety of trastuzumab emtansine (T-DM1) for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer. METHODS:We performed a systemic review and meta-analysis of the relevant published clinical studies. A c...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S100499

    authors: Ma B,Ma Q,Wang H,Zhang G,Zhang H,Wang X

    更新日期:2016-02-29 00:00:00

  • Retraction.

    abstract::[This retracts the article on p. 2215 in vol. 8, PMID: 26345468.]. ...

    journal_title:OncoTargets and therapy

    pub_type: 撤回出版物

    doi:10.2147/OTT.S100941

    authors:

    更新日期:2016-02-04 00:00:00

  • AZIN1-AS1, A Novel Oncogenic LncRNA, Promotes the Progression of Non-Small Cell Lung Cancer by Regulating MiR-513b-5p and DUSP11.

    abstract:Background:Emerging researches have demonstrated that aberrantly expressed long non-coding RNAs (lncRNAs) have great significance in non-small cell lung cancer (NSCLC) progression. The aim of this study was to explore the role of lncRNA AZIN1 antisense RNA 1 (AZIN1-AS1) in NSCLC and the related mechanism. Methods:Expr...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S261497

    authors: Cai Y,Wu Q,Liu Y,Wang J

    更新日期:2020-10-09 00:00:00

  • Differential radiation response between normal astrocytes and glioma cells revealed by comparative transcriptome analysis.

    abstract::Normal astrocytes are more resistant to radiation than glioma cells. Radiation-resistant glioma cells and normal astrocytes usuallly share similar mechanisms of radioresistance. Investigation of the underlying mechanisms of differential radiation response between normal astrocytes and glioma cells is thus significant ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S144002

    authors: Gong L,Gu J,Ge J,Wu X,Zhang C,Yang C,Weng W,Gao G,Feng J,Mao Q

    更新日期:2017-12-04 00:00:00

  • ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2/STAT3 pathway.

    abstract::Increasing evidence has shown that aldehyde dehydrogenase 1A1 (ALDH1A1), a detoxifying enzyme, is responsible for chemoresistance in a variety of tumors. Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), che...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S107957

    authors: Jiang J,Liu Y,Tang Y,Li L,Zeng R,Zeng S,Zhong M

    更新日期:2016-08-29 00:00:00

  • Knockdown of long noncoding RNA 00152 (LINC00152) inhibits human retinoblastoma progression.

    abstract:Background:A growing body of evidence supports the involvement of long noncoding RNA 00152 (LINC00152) in the progression and metastasis of multiple cancers. However, the exact roles of LINC00152 in the progression of human retinoblastoma (RB) remain unknown. We explored the expression and biological function of human ...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S160428

    authors: Li S,Wen D,Che S,Cui Z,Sun Y,Ren H,Hao J

    更新日期:2018-06-06 00:00:00

  • CircRNA-PTN Sponges miR-326 to Promote Proliferation in Hepatocellular Carcinoma.

    abstract:Background:Mounting evidences reveal that circular RNAs (circRNAs) are critical to regulate biological behavior and process of tumor. Our objective is to explore the role of circRNA-PTN (circPTN) and explain the exact mechanism in hepatocellular carcinoma (HCC). Methods:Real-time polymerase chain reaction assay was us...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S251300

    authors: Jia B,Yin X,Wang Y,Qian J,He Y,Yang C,Yu G,Guo B,Meng X

    更新日期:2020-05-29 00:00:00

  • Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis.

    abstract:Background:Melatonin (MLT), a kind of neuroendocrine active substance, has been reported to function in the treatment of tumors. However, there remain controversies about the curative effect of MLT in tumors in clinical studies. This study investigates the efficacy of MLT on tumor therapeutic strategies by meta-analysi...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S174100

    authors: Wang Y,Wang P,Zheng X,Du X

    更新日期:2018-11-08 00:00:00

  • MicroRNA-497-5p Induces Cell Cycle Arrest Of Cervical Cancer Cells In S Phase By Targeting CBX4.

    abstract:Purpose:miR-497-5p can inhibit cervical cancer cell proliferation. However, the underlying mechanism remains to be elucidated. Methods:Bioinformatics was used to analyze the target genes of miR-497-5p. qRT-PCR and Western blot were used to analyze mRNA and protein expression, respectively. Dual-luciferase reporter ass...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S210059

    authors: Chen Y,Du J,Wang Y,Shi H,Jiang Q,Wang Y,Zhang H,Wei Y,Xue W,Pu Z,Gao Y,Li D,Feng Y,Yan J,Zhang J

    更新日期:2019-12-02 00:00:00

  • MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting HMGA2.

    abstract:Background:Growing evidence suggests that miR-150 plays an inhibitory role in various types of cancer. However, the function and underlying mechanisms of miR-150 in triple-negative breast cancer (TNBC) remain unknown. Patients and methods:miR-150 expression was detected by qRT-PCR and ISH in TNBC tumor and adjacent no...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S161996

    authors: Tang W,Xu P,Wang H,Niu Z,Zhu D,Lin Q,Tang L,Ren L

    更新日期:2018-04-24 00:00:00

  • Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis.

    abstract::miRNAs (miRs) are short RNA molecules that are involved in the posttranscriptional regulation of mRNA. The roles of miRs in tumor pathogenesis have only recently become a focus of research. It is becoming increasingly clear that miRs are important regulators of apoptosis, proliferation, invasion, and metastasis in can...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S52730

    authors: Cheng Q,Yi B,Wang A,Jiang X

    更新日期:2013-11-18 00:00:00

  • Sirtuin-4 (SIRT4), a therapeutic target with oncogenic and tumor-suppressive activity in cancer.

    abstract::Several members of the sirtuin (SIRT) family, a highly conserved family of NAD+-dependent enzymes, have been shown to play a critical role in both promoting and/or suppressing tumorigenesis. In this study, recent progress in the field concerning SIRT4 and cancer was reviewed, and the relationship between SIRT4 and tum...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S157724

    authors: Huang G,Zhu G

    更新日期:2018-06-11 00:00:00

  • Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors.

    abstract::Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor, and surgical resection is the first choice for the treatment of the disease, but since the advent of tyrosine kinase inhibitors (TKIs) such as imatinib (IM), the prognosis of the disease has undergone revolutionary changes. According to the cu...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S279998

    authors: Xu H,Liu Q

    更新日期:2021-01-05 00:00:00

  • Association of MLH1 single nucleotide polymorphisms with clinical outcomes of first-line irinotecan-based chemotherapy in colorectal cancer.

    abstract:Purpose:Several studies have proved that single nucleotide polymorphisms (SNPs) of mismatch repair system genes are closely related to the development of colorectal cancer (CRC) by causing microsatellite instability, while effects of the SNPs of MMR system-related genes on the clinical outcomes of cytotoxic chemotherap...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S180145

    authors: Wang D,Zhang X,Zhang Y,Wu Y,Guan X,Zhu W,Wang M,Qi C,Shen B

    更新日期:2018-11-13 00:00:00

  • Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients.

    abstract::Anterior gradient protein (AGR) 3 is a highly related homologue of pro-oncogenic AGR2 and belongs to the family of protein disulfide isomerases. Although AGR3 was found in breast, ovary, prostate, and liver cancer, it remains of yet poorly defined function in tumorigenesis. This study aimed to determine AGR3 expressio...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S82235

    authors: Obacz J,Brychtova V,Podhorec J,Fabian P,Dobes P,Vojtesek B,Hrstka R

    更新日期:2015-06-24 00:00:00

  • Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.

    abstract::Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%-3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the c...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S141053

    authors: Donato EM,Fernández-Zarzoso M,Hueso JA,de la Rubia J

    更新日期:2018-08-06 00:00:00

  • Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date.

    abstract::Advances in therapies have led to the approval of six therapeutic agents since 2004, each demonstrating overall survival benefit in randomized studies, and these have significantly improved the outlook for men facing metastatic castration-resistant prostate cancer (CRPC). More recently, efforts have been directed at t...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章,评审

    doi:10.2147/OTT.S147168

    authors: Chong JT,Oh WK,Liaw BC

    更新日期:2018-04-12 00:00:00

  • The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer.

    abstract:BACKGROUND:C-X-C chemokine receptor type 4 (CXCR4) is involved in tumor progression including angiogenesis, metastasis, and survival. However, whether serum CXCR4 levels in metastatic or recurrent colorectal cancer have a prognostic role, have not been evaluated. METHODS:We analyzed serum samples from 55 patients with...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S104511

    authors: Choi YJ,Chang WJ,Shin SW,Park KH,Kim ST,Kim YH

    更新日期:2016-06-01 00:00:00

  • KIF18B promotes tumor progression through activating the Wnt/β-catenin pathway in cervical cancer.

    abstract:Background:KIF18B was identified as a potential oncogene by analysis of The Cancer Genome Atlas database. Materials and methods:We assessed KIF18B expression and explored its clinical significance in cervical cancer tissues. We have also evaluated the effects of KIF18B on cervical cancer cell proliferation, migration,...

    journal_title:OncoTargets and therapy

    pub_type: 杂志文章

    doi:10.2147/OTT.S157440

    authors: Wu Y,Wang A,Zhu B,Huang J,Lu E,Xu H,Xia W,Dong G,Jiang F,Xu L

    更新日期:2018-03-28 00:00:00

  • Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small-Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study).

    abstract:Background:Few data have been published on the clinical and histopathological characteristics of advanced non-small-cell lung cancer (NSCLC) patients with high PD-L1 expression versus intermediate or none and the prognostic value of PD-L1 expression for patients treated with chemotherapy is unknown. This study was unde...

    journal_title:OncoTargets and therapy

    pub_type: 临床试验

    doi:10.2147/OTT.S288825

    authors: Auliac JB,Guisier F,Bizieux A,Assouline P,Bernardini M,Lamy R,Justeau G,François G,Damotte D,Chouaïd C

    更新日期:2020-12-30 00:00:00